دورية أكاديمية
أعرض في EDS

Misleading advertising for antidepressants in Sweden: a failure of pharmaceutical industry self-regulation.

التفاصيل البيبلوغرافية
العنوان: Misleading advertising for antidepressants in Sweden: a failure of pharmaceutical industry self-regulation.
المؤلفون: Zetterqvist AV; Department of Clinical Sciences, Lund University, Malmö, Sweden., Mulinari S
المصدر: PloS one [PLoS One] 2013 May 01; Vol. 8 (5), pp. e62609. Date of Electronic Publication: 2013 May 01 (Print Publication: 2013).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Antidepressive Agents*, Advertising/*economics, Drug Industry/economics ; Drug Industry/ethics ; Drug Industry/legislation & jurisprudence ; Fraud ; Humans ; Legislation, Drug ; Periodicals as Topic ; Social Control, Informal ; Sweden
مستخلص: Background: The alleged efficacy of pharmaceutical industry self-regulation has been used to repudiate increased government oversight over promotional activity. European politicians and industry have cited Sweden as an excellent example of self-regulation based on an ethical code. This paper considers antidepressant advertising in Sweden to uncover the strengths and weaknesses of self-regulation.
Methodology: We analyzed all antidepressant advertisements in the Swedish Medical Journal, 1994-2003. The regulation of these advertisements was analyzed using case reports from self-regulatory bodies. The authors independently reviewed this material to investigate: (1) extent of violative advertising; (2) pattern of code breaches; (3) rate at which the system reacted to violative advertising; (4) prevalence of and oversight over claims regarding antidepressant efficacy and disease causality, and (5) costs for manufactures associated with violative advertising.
Principal Findings: Self-regulatory bodies identified numerous code breaches. Nonetheless, they failed to protect doctors from unreliable information on antidepressants, since as many as 247 of 722 (34%) advertisements breached the industry code. Self-regulatory bodies repeatedly failed to challenge inflated claims of antidepressant efficacy, lending evidence of lax oversight. On average, 15 weeks elapsed between printing and censure of a wrongful claim, and in 25% of cases 47 weeks or more elapsed. Industry paid roughly €108000 in fines for violative advertising, adding an estimated additional average cost of 11% to each purchased violative advertisement, or amounting to as little as 0.009% of total antidepressant sales of around €1.2 billion.
Conclusions: Lax oversight, combined with lags in the system and low fines for violations, may explain the Swedish system's failure to pressure companies into providing reliable antidepressants information. If these shortcomings prove to be consistent across self-regulatory settings, and if appropriate measures are not taken to amend shortcomings, many countries may want to reconsider the current balance between self-regulation, and legislative control with government oversight.
References: N Engl J Med. 2008 Jan 17;358(3):252-60. (PMID: 18199864)
Pharmacoeconomics. 2008;26(7):603-16. (PMID: 18563951)
Neth J Med. 2010 Jan;68(1):46-9. (PMID: 20103825)
Sociol Health Illn. 2013 Jun;35(5):761-77. (PMID: 23094890)
Arch Gen Psychiatry. 2009 Aug;66(8):848-56. (PMID: 19652124)
Global Health. 2012 Jul 11;8:24. (PMID: 22784944)
J Pharm Bioallied Sci. 2011 Jul;3(3):403-6. (PMID: 21966161)
J Hist Neurosci. 2012;21(4):366-92. (PMID: 22947380)
PLoS Med. 2005 Dec;2(12):e392. (PMID: 16268734)
Med J Aust. 2005 Jul 18;183(2):73-4. (PMID: 16022611)
PLoS One. 2009 Jul 22;4(7):e6350. (PMID: 19623259)
PLoS Med. 2008 Feb;5(2):e45. (PMID: 18303940)
Eur Neuropsychopharmacol. 2008 Sep;18(9):623-7. (PMID: 18621509)
BMC Public Health. 2010 May 29;10:294. (PMID: 20509953)
Lancet. 2003 Mar 8;361(9360):878-9. (PMID: 12642074)
Pharmacoepidemiol Drug Saf. 2004 Nov;13(11):789-95. (PMID: 15486957)
Lakartidningen. 2011 Sep 21-27;108(38):1839-40. (PMID: 22111217)
Am J Bioeth. 2003 Summer;3(3):49-50. (PMID: 14594491)
Arch Gen Psychiatry. 1974 Apr;30(4):447-51. (PMID: 4273761)
BMJ. 2003 May 31;326(7400):1171-3. (PMID: 12775615)
Lancet. 2003 Jan 4;361(9351):27-32. (PMID: 12517463)
Br J Psychiatry. 2012 May;200(5):393-8. (PMID: 22442100)
N Engl J Med. 1990 Aug 30;323(9):616-7. (PMID: 2381456)
PLoS Med. 2006 May;3(6):e130. (PMID: 16637744)
BMJ. 2005 Nov 26;331(7527):1225. (PMID: 16308367)
PLoS One. 2011;6(8):e23336. (PMID: 21858076)
CMAJ. 1997 Feb 1;156(3):351-6. (PMID: 9033415)
Int J Clin Pract. 2010 Jul;64(8):1015-8. (PMID: 20642702)
Lakartidningen. 2012 Nov 14-20;109(46):2106-7. (PMID: 23259219)
PLoS Med. 2010 Oct 19;7(10):e1000352. (PMID: 20976098)
BMJ. 1990 Feb 3;300(6720):307-11. (PMID: 2106963)
J Nerv Ment Dis. 2008 Apr;196(4):267-73. (PMID: 18414120)
Rheumatology (Oxford). 2006 Sep;45(9):1154-7. (PMID: 16531437)
Arch Gen Psychiatry. 1997 Jul;54(7):597-606. (PMID: 9236543)
المشرفين على المادة: 0 (Antidepressive Agents)
تواريخ الأحداث: Date Created: 20130508 Date Completed: 20131126 Latest Revision: 20240319
رمز التحديث: 20240319
مُعرف محوري في PubMed: PMC3641086
DOI: 10.1371/journal.pone.0062609
PMID: 23650519
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0062609